Bioavailability of a sustained release formulation of curcumin

Integrative Medicine (Boulder)

Volumn 13, Issue 3, 2014, Pages 24-30

  Madhavi, Doddabele ^a   Kagan, Daniel ^a  

^a BioActives LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84929032518     PISSN: 1546993X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (21)

1. Sharma O P. Antioxidant activity of curcumin and related compounds. Biochem Pharmacol. 1976; 25(15):1811-1812.
2. Jurenka JS Anti-inflammatory properties of curcumin, a major constituent of Curcuma longa: a review of preclinical and clinical research. Altern Med Rev. 2009; 14(2):141-153.
3. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23(1A):363-398.
4. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007; 4(6):807-818.
5. Lao CD, Ruffin MT IV, Normolle D, et al. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. March 2006; 6:10-13.
6. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10(20):6847-6854.
7. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21(4B):2895-2900.
8. Hu L, Jia Y, Niu F, Jia Z, Yang X, Jiao K. Preparation and enhancement of oral bioavailability of curcumin using microemulsions vehicle. J Agric Food Chem. 2012; 60(29):7137-7141.
9. Ramshankar Y V, Suresh S, Devi K. Novel self-emulsifying formulation of curcumin with improved dissolution, antiangiogenic and anti-inflammatory activity. Clin Res Regul Aff. 2008; 25(4):213-234.
10. Sasaki H, Sunagawa Y, Takahashi K, et al. Innovative preparation of curcumin for improved oral bioavailability. Biol Pharm Bull. 2011; 34(5):660-665.
11. Bisht S, Feldmann G, Soni S, et al. Polymeric nanoparticle-encapsulated curcumin ("nanocurcumin"): a novel strategy for human cancer therapy. J Nanobiotechnology. April 2007; 5:3.
12. The United States Pharmacopeia-National Formulary. 23rd ed. Rockville, MD: United States Pharmacopeial Convention; 1995:1795-1796.
13. Vareed SK, Kakarala M, Ruffin MT, et al. Pharamcokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008; 17(6):1411-1417.
14. Cuomo J, Appendino G, Dern AS, et al. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod. 2011; 74(4):664-669.
15. Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, Kobayashi M. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci U S A. 2011; 108(16):6615-6620.
16. Fleschhut J, Kratzer F, Rechkemmer G, Kulling SE. Stability and biotransformation of various dietary anthocyanins in vitro. Eur J Nutr. 2006; 45(1):7-18.
17. Ahmed T, Gilani AH. A comparative study of curcuminoids to measure their effect on inflammatory and apoptotic gene expression in an Aβ plus ibotenic acid-infused rat model of Alzheimer's disease. Brain Res. July 2011; 1400:1-18.
18. Liu YL, Yang H P, Zhou XD, Gong L, Tang CL, Wang HJ. The hypomethylation agent bisdemethoxycurcumin acts on the WIF-1 promoter, inhibits the canonical Wnt pathway and induces apoptosis in human non-small-cell lung cancer. Curr Cancer Drug Targets. 2011; 11(9):1098-1110.
19. Boonrao M, Yodkeeree S, Ampasavate C, Anuchapreeda S, Limtrakul P. The inhibitory effect of turmeric curcuminoids on matrix metalloproteinase-3 secretion in human invasive breast carcinoma cells. Arch Pharm Res. 2010; 33(7):989-998.
20. Zhang LJ, Wu CF, Meng XL, et al. Comparison of inhibitory potency of three different curcuminoid pigments on nitric oxide and tumor necrosis factor production of rat primary microglia induced by lipopolysaccharide. Neurosci Lett. 2008; 447(1):48-53.
21. Lee J W, Hong HM, Kwon DD, Pae HO, Jeong HJ. Demethoxycurcumin, a structural analogue of curcumin, induces apoptosis in human renal carcinoma caki cells through the production of reactive oxygen species, the release of cytochrome C, and the activation of caspase-3. Korean J Urol. 2010; 51(12):870-888.